Kathelijn Fischer

List of Publications by Year
in descending order

184	7,338	53751 45	66879 78
papers	citations	h-index	g-index

189	189	189	3302
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen. Thrombosis and Haemostasis, 2022, 122, 208-215.	1.8	7
2	Bone mineral density in haemophilia â€“ a multicentre study evaluating the impact of different replacement regimens. Haemophilia, 2022, 28, 239-246.	1.0	2
3	Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A. HemaSphere, 2022, 6, e679.	1.2	7
4	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances, 2022, 6, 902-908.	2.5	15
5	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere, 2022, 6, e694.	1.2	1
6	Sports participation of patients with haemophilia in the COVIDâ€19 era: The Dutch experience. Haemophilia, 2021, 27, e295-e297.	1.0	6
7	Assessing the testâ€“retest reliability and smallest detectable change of the Haemophilia Activities List. Haemophilia, 2021, 27, 108-112.	1.0	12
8	Shortening the paediatric Haemophilia Activities List (pedHAL) based on pooled data from international studies. Haemophilia, 2021, 27, 305-313.	1.0	3
9	Sports participation is not associated with adherence to prophylaxis in Dutch patients with haemophilia. Haemophilia, 2021, 27, e402-e405.	1.0	3
10	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	1.0	20
11	PROTECT VIII kids extension study: Longâ€term safety and efficacy of BAY 94â€9027 (damoctocog alfa pegol) in children with severe haemophilia A. Haemophilia, 2021, 27, 434-444.	1.0	8
12	Role of Regulatory Cells in Immune Tolerance Induction in Hemophilia A. HemaSphere, 2021, 5, e557.	1.2	2
13	Adherence to prophylaxis and its association with activation of selfâ€management and treatment satisfaction. Haemophilia, 2021, 27, 581-590.	1.0	8
14	A tailored intervention for illness acceptance improves adherence and quality of life in adults with haemophilia using prophylaxis. Haemophilia, 2021, 27, e434-e440.	1.0	1
15	Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2021, 47, 724-734.	1.5	3
16	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. Haemophilia, 2021, 27, 876-885.	1.0	14
17	Haemophilia. Nature Reviews Disease Primers, 2021, 7, 45.	18.1	103
18	Terminal halfâ€life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis, 2021, 19, 1896-1906.	1.9	12

#	Article	IF	Citations
19	Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Advances, 2021, 5, 2732-2739.	2.5	11
20	Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review. Clinical Pharmacokinetics, 2021, 60, 1395-1406.	1.6	19
21	European principles of care for women and girls with inherited bleeding disorders. Haemophilia, 2021, 27, 837-847.	1.0	23
22	A qualitative study on the experiences of haemophilia carriers before, during and after pregnancy. Haemophilia, 2021, 27, e675-e682.	1.0	4
23	Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items. Haemophilia, 2021, 27, 1062-1070.	1.0	6
24	Generic PROMIS item banks in adults with hemophilia for patientâ€reported outcome assessment: Feasibility, measurement properties, and relevance. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12621.	1.0	8
25	Detecting low blood concentrations in joints using T1 and T2 mapping at 1.5, 3, and 7 T: an in vitro study. European Radiology Experimental, 2021, 5, 51.	1.7	5
26	Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia, 2020, 26, 1072-1080.	1.0	14
27	Novel F8 and F9 gene variants from the PedNet hemophilia registry classified according to ACMG/AMP guidelines. Human Mutation, 2020, 41, 2058-2072.	1.1	4
28	The factor VIII treatment history of nonâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 3203-3210.	1.9	15
29	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	1.0	4
30	A feasibility study on two tailored interventions to improve adherence in adults with haemophilia. Pilot and Feasibility Studies, 2020, 6, 189.	0.5	8
31	MRI predicts 5-year joint bleeding and development of arthropathy on radiographs in hemophilia. Blood Advances, 2020, 4, 113-121.	2.5	29
32	Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica, 2020, 106, 123-129.	1.7	60
33	Adherence to prophylaxis and bleeding in children: Significant drop during puberty but no correlation with bleeding. Haemophilia, 2020, 26, e240-e243.	1.0	3
34	Longâ€term safety and sustained efficacy for up to 5Âyears of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the Bâ€YOND extension study. Haemophilia, 2020, 26, e262-e271.	1.0	28
35	PROTECT VIII Kids: BAY 94â€9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. Haemophilia, 2020, 26, e55-e65.	1.0	20
36	Comparison between coagulation factor VIII quantified with oneâ€stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle. International Journal of Laboratory Hematology, 2020, 42, 819-826.	0.7	2

#	Article	IF	Citations
37	The Perspectives of Adolescents and Young Adults on Adherence to Prophylaxis in Hemophilia: A Qualitative Study . Patient Preference and Adherence, 2020, Volume 14, 163-171.	0.8	10
38	Sports participation and sports injuries in Dutch boys with haemophilia. Scandinavian Journal of Medicine and Science in Sports, 2020, 30, 1256-1264.	1.3	17
39	The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review. Journal of Thrombosis and Haemostasis, 2020, 18, 1626-1636.	1.9	12
40	Use of ultrasound for assessment of musculoskeletal disease in persons with haemophilia: Results of an International Prophylaxis Study Group global survey. Haemophilia, 2020, 26, 685-693.	1.0	16
41	BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study. Blood, 2020, 136, 40-41.	0.6	2
42	Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc. TH Open, 2020, 04, e362-e364.	0.7	2
43	Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database. Blood, 2020, 136, 21-22.	0.6	1
44	The Paediatric Haemophilia Activities List (pedHAL) in routine assessment: changes over time, childâ€parent agreement and informative domains. Haemophilia, 2019, 25, 953-959.	1.0	9
45	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 2019, 134, 317-320.	0.6	71
46	Impact of prophylaxis on healthâ€related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 397-404.	1.0	12
47	Sports participation and physical activity in adult Dutch and Swedish patients with severe haemophilia: A comparison between intermediateâ€and highâ€dose prophylaxis. Haemophilia, 2019, 25, 244-251.	1.0	16
48	Review of immune tolerance induction in hemophilia A. Blood Reviews, 2018, 32, 326-338.	2.8	51
49	Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions. Haemophilia, 2018, 24, 177-179.	1.0	2
50	Measuring activities and participation in persons with haemophilia: A systematic review of commonly used instruments. Haemophilia, 2018, 24, e33-e49.	1.0	21
51	Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia, 2018, 24, 283-290.	1.0	24
52	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. Thrombosis and Haemostasis, 2018, 118, 1690-1700.	1.8	10
53	Positioning extended halfâ€life concentrates for future use: a practical proposal. Haemophilia, 2018, 24, e369-e372.	1.0	4
54	Diagnostic accuracy of pointâ€ofâ€care ultrasound for evaluation of early bloodâ€induced joint changes: Comparison with <scp>MRI</scp>. Haemophilia, 2018, 24, 971-979.	1.0	29

#	Article	IF	Citations
55	No Relation between Platelet Activity and Haemophilia B Phenotype. Thrombosis and Haemostasis, 2018, 118, 1481-1483.	1.8	0
56	BAY 94â€9027, a PEGylated recombinant factor VIII, exhibits a prolonged halfâ€life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies. Haemophilia, 2018, 24, 733-740.	1.0	33
57	Continuous infusion of extended halfâ€life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Haemophilia, 2018, 24, e280-e283.	1.0	8
58	Primary prophylaxis in haemophilia care: Guideline update 2016. Blood Cells, Molecules, and Diseases, 2017, 67, 81-85.	0.6	29
59	Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematology,the, 2017, 4, e75-e82.	2.2	61
60	Safety, efficacy and pharmacokinetics of rVIIIâ€SingleChain in children with severe hemophilia A: results of a multicenter clinical trial. Journal of Thrombosis and Haemostasis, 2017, 15, 636-644.	1.9	26
61	Large scale studies assessing antiâ€factor <scp>VIII</scp> antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. British Journal of Haematology, 2017, 178, 20-31.	1.2	10
62	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. Haematologica, 2017, 102, 1486-1493.	1.7	24
63	Comparing findings of routine Haemophilia Joint Health Score and Haemophlia Early Arthropathy Detection with UltraSound assessments in adults with haemophilia. Haemophilia, 2017, 23, e141-e143.	1.0	33
64	Comparing thrombin generation in patients with hemophilia A and patients on vitamin K antagonists. Journal of Thrombosis and Haemostasis, 2017, 15, 868-875.	1.9	14
65	Do the SIPPET study results apply to the patients I treat?. Haemophilia, 2017, 23, 348-349.	1.0	12
66	Monitoring joint health in haemophilia: Factors associated with deterioration. Haemophilia, 2017, 23, 934-940.	1.0	36
67	Imaging of haemophilic arthropathy: Awareness of pitfalls and need for standardization. Haemophilia, 2017, 23, 645-647.	1.0	11
68	Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective. Haemophilia, 2017, 23, 11-24.	1.0	63
69	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B. Thrombosis and Haemostasis, 2017, 117, 508-518.	1.8	31
70	Pathophysiological Mechanisms of Endogenous FVIII Release following Strenuous Exercise in Non-severe Haemophilia: A Review. Thrombosis and Haemostasis, 2017, 117, 2237-2242.	1.8	5
71	Discontinuing early prophylaxis in severe haemophilia leads to deterioration of joint status despite low bleeding rates. Thrombosis and Haemostasis, 2016, 115, 931-938.	1.8	36
72	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11

#	Article	IF	Citations
73	Defining adherence to prophylaxis in haemophilia. Haemophilia, 2016, 22, e311-4.	1.0	13
74	Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed. Haemophilia, 2016, 22, 142-147.	1.0	35
75	Lowâ€dose prophylaxis for severe haemophilia: a little goes a long way. Haemophilia, 2016, 22, 331-333.	1.0	13
76	Evaluating outcome of prophylaxis in haemophilia: objective and selfâ€reported instruments should be combined. Haemophilia, 2016, 22, e80-e86.	1.0	29
77	Value of routine ultrasound in detecting early joint changes in children with haemophilia using the â€˜Haemophilia Early Arthropathy Detection with UltraSoundâ€™ protocol. Haemophilia, 2016, 22, 121-125.	1.0	41
78	Achieving self-management of prophylactic treatment in adolescents: The case of haemophilia. Patient Education and Counseling, 2016, 99, 1179-1183.	1.0	14
79	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. Blood, 2016, 128, 630-637.	0.6	69
80	Evidence for and costâ€effectiveness of physiotherapy in haemophilia: a Dutch perspective. Haemophilia, 2016, 22, 943-948.	1.0	8
81	Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia, 2016, 22, e375-82.	1.0	8
82	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1105-1109.	1.9	54
83	Longâ€term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia, 2016, 22, 852-858.	1.0	19
84	The association of haemophilic arthropathy with Healthâ€Related Quality of Life: a post hoc analysis. Haemophilia, 2016, 22, 833-840.	1.0	26
85	Promoting selfâ€management and adherence during prophylaxis: evidenceâ€based recommendations for haemophilia professionals. Haemophilia, 2016, 22, 499-506.	1.0	31
86	Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre study. British Journal of Haematology, 2016, 174, 454-460.	1.2	46
87	Selfâ€infusion of prophylaxis: evaluating the quality of its performance and time needed. Haemophilia, 2016, 22, e214-7.	1.0	2
88	Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. Haemophilia, 2016, 22, 514-520.	1.0	58
89	Scoring haemophilic arthropathy on X-rays: improving inter- and intra-observer reliability and agreement using a consensus atlas. European Radiology, 2016, 26, 1963-1970.	2.3	21
90	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	0.6	3

#	Article	IF	Citations
91	Multiple joint procedures in haemophilia: benefit of self-reported activities. The Journal of Haemophilia Practice, 2016, 3, 55-61.	0.2	0
92	Risk Factors for the Development of High-Titer Inhibitors in 260 Children with Severe Hemophilia a Born Between 1990 and 2009: The Remain Study. Blood, 2016, 128, 3774-3774.	0.6	0
93	Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?. Seminars in Thrombosis and Hemostasis, 2015, 41, 860-863.	1.5	13
94	Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica, 2015, 100, e84-e86.	1.7	27
95	International crossâ€cultural validation study of the Canadian Haemophilia Outcomes: Kidsâ€™ Life Assessment Tool. Haemophilia, 2015, 21, 351-357.	1.0	26
96	Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis, 2015, 114, 670-675.	1.8	14
97	Assessments of outcome in haemophilia â€“ what is the added value of <scp>QoL</scp> tools?. Haemophilia, 2015, 21, 430-435.	1.0	25
98	Unravelling adherence to prophylaxis in haemophilia: a patientsâ€™ perspective. Haemophilia, 2015, 21, 612-621.	1.0	32
99	Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis, 2015, 113, 968-975.	1.8	103
100	How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia, 2015, 21, 444-450.	1.0	28
101	Limits of agreement between raters are required for the use of <scp>HJHS</scp> 2.1 in clinical studies. Haemophilia, 2015, 21, e70-1.	1.0	2
102	Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A. Haemophilia, 2015, 21, 227-233.	1.0	18
103	Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. Journal of Hepatology, 2014, 60, 39-45.	1.8	52
104	Cost Effectiveness Analysis Evaluating Factor Viii As Primary Prophylaxis Treatment for Patients With Severe Haemophilia A In the Netherlands. Value in Health, 2014, 17, A531.	0.1	0
105	Haemophilia Joint Health Score in healthy adults playing sports. Haemophilia, 2014, 20, 282-286.	1.0	29
106	Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia, 2014, 20, e280-6.	1.0	60
107	Prophylaxis in real life scenarios. Haemophilia, 2014, 20, 106-113.	1.0	22
108	Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. Blood, 2014, 124, 2818-2818.	0.6	1

#	Article	IF	Citations
109	No Association Between Platelet Function and Hemophilia B Phenotype. Blood, 2014, 124, 4994-4994.	0.6	1
110	Modeling Minimally-Effective FVIII Trough Levels in Hemophilia a Patients on PK-Guided Prophylaxis. Blood, 2014, 124, 689-689.	0.6	4
111	The European Haemophilia Network (EUHANET). Blood Transfusion, 2014, 12 Suppl 3, s515-8.	0.3	11
112	Quality of haemophilia care in The Netherlands: new standards for optimal care. Blood Transfusion, 2014, 12 Suppl 3, s501-4.	0.3	8
113	Treatment for life for severe haemophilia Aâ€“ A costâ€utility model for prophylaxis vs. onâ€demand treatment. Haemophilia, 2013, 19, e228-38.	1.0	48
114	Protected by nature? Effects of strenuous physical exercise on FVIII activity in moderate and mild haemophilia A patients: a pilot study. Haemophilia, 2013, 19, 519-523.	1.0	26
115	Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia, 2013, 19, 355-361.	1.0	80
116	The European Principles of Haemophilia Care: a pilot investigation of adherence to the principles in Europe. Haemophilia, 2013, 19, 35-43.	1.0	29
117	Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood, 2013, 122, 1129-1136.	0.6	200
118	Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia, 2013, 19, 944-950.	1.0	72
119	Estimating unknown parameters in haemophilia using expert judgement elicitation. Haemophilia, 2013, 19, e282-8.	1.0	13
120	Functional limitations in <scp>R</scp>omanian children with haemophilia: further testing of psychometric properties of the <scp>P</scp>aediatric <scp>H</scp>aemophilia <scp>A</scp>ctivities <scp>L</scp>ist. Haemophilia, 2013, 19, e116-25.	1.0	19
121	Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood, 2013, 121, 4046-4055.	0.6	287
122	Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thrombosis and Haemostasis, 2013, 109, 16-23.	1.8	62
123	Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?. Blood Transfusion, 2013, 11, 364-9.	0.3	25
124	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood, 2012, 119, 612-618.	0.6	181
125	Health-related quality of life. The effect of pelvic floor muscle training and midurethral sling surgery: a systematic review. International Urogynecology Journal, 2012, 23, 1155-1162.	0.7	8
126	Requirements for immune recognition and processing of factor VIII by antigen-presenting cells. Blood Reviews, 2012, 26, 43-49.	2.8	17

#	Article	IF	Citations
127	Validity of assessing inhibitor development in haemophilia PUPs using registry data: the EUHASS project. Haemophilia, 2012, 18, e241-6.	1.0	36
128	Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia, 2012, 18, 516-520.	1.0	31
129	Models of prophylaxis. Haemophilia, 2012, 18, 136-140.	1.0	16
130	Determinants of participation in patients with severe haemophilia. Haemophilia, 2012, 18, 860-867.	1.0	7
131	Effects of Vaginal Prolapse Surgery on Sexuality in Women and Men; Results from a RCT on Repair With and Without Mesh. Journal of Sexual Medicine, 2012, 9, 1200-1211.	0.3	28
132	Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfusion, 2012, 10, 169-73.	0.3	25
133	EUHASS: The European Haemophilia Safety Surveillance system. Thrombosis Research, 2011, 127, S22-S25.	0.8	76
134	Coping style and health-related quality of life in caregivers of epilepsy patients. Journal of Neurology, 2011, 258, 1788-1794.	1.8	33
135	A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica, 2011, 96, 738-743.	1.7	30
136	Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia, 2011, 17, 2-10.	1.0	170
137	Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia, 2011, 17, 41-44.	1.0	174
138	Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia, 2011, 17, 433-438.	1.0	41
139	Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study. Haemophilia, 2011, 17, 926-930.	1.0	38
140	Clinical severity of haemophilia A: does the classification of the 1950s still stand?. Haemophilia, 2011, 17, 849-853.	1.0	212
141	Habitual physical activity in Dutch children and adolescents with haemophilia. Haemophilia, 2011, 17, e906-12.	1.0	34
142	Use of the CD19 count in a primary care laboratory as a screening method for B-cell chronic lymphoproliferative disorders in asymptomatic patients with lymphocytosis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 115-20.	1.4	7
143	Coping style and quality of life in patients with epilepsy: a cross-sectional study. Journal of Neurology, 2011, 258, 37-43.	1.8	57
144	Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units. Haemophilia, 2010, 16, 71-79.	1.0	24

#	Article	IF	Citations
145	Starreveld scoring method in diagnosing childhood constipation. Pediatric Radiology, 2010, 40, 1789-1793.	1.1	7
146	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Journal of Thrombosis and Haemostasis, 2010, 8, 269-275.	1.9	176
147	Comparative pharmacokinetics of plasmaâ€•and albuminâ€free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed ageâ€related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 2010, 8, 730-736.	1.9	115
148	Development and preliminary testing of a Paediatric Version of the Haemophilia Activities List (<scp>p</scp>ed<scp>hal</scp>). Haemophilia, 2010, 16, 281-289.	1.0	42
149	Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. Haemophilia, 2010, 16, 892-901.	1.0	18
150	Protected by Nature: Effects of Exercise In Non-Severe Haemophilia Patients. Blood, 2010, 116, 545-545.	0.6	0
151	Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia, 2009, 15, 83-90.	1.0	90
152	Breakâ€through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 413-420.	1.9	295
153	Quality of life of caregivers of patients with intractable epilepsy. Epilepsia, 2009, 50, 1294-1296.	2.6	41
154	Exposure to chemicals and metals and risk of amyotrophic lateral sclerosis: A systematic review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 302-309.	2.3	124
155	What we truly know about occupation as a risk factor for ALS: A critical and systematic review. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 295-301.	2.3	69
156	Models for Prediction of Factor VIII Half-Life in Severe Haemophiliacs: Distinct Approaches for Blood Group O and Non-O Patients. PLoS ONE, 2009, 4, e6745.	1.1	56
157	European principles of haemophilia care. Haemophilia, 2008, 14, 361-374.	1.0	191
158	Can we consider discontinuing primary prophylaxis in adults with severe haemophilia?. Haemophilia, 2008, 14, 10-10.	1.0	92
159	Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia, 2008, 14, 196-201.	1.0	34
160	LASER-ASSISTED ENDOSCOPIC THIRD VENTRICULOSTOMY. Neurosurgery, 2008, 62, 437-444.	0.6	42
161	Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis. Thrombosis and Haemostasis, 2008, 99, 965-965.	1.8	5
162	RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia. Haemophilia, 2007, 13, 345-350.	1.0	18

#	Article	IF	Citations
163	Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group. Haemophilia, 2007, 14, 071115150757005-???.	1.0	24
164	The natural history of childhood-acquired hepatitis C infection in patients with inherited bleeding disorders. Transfusion, 2006, 46, 1360-1366.	0.8	24
165	Effects of haemophilic arthropathy on health-related quality of life and socio-economic parameters. Haemophilia, 2005, 11, 43-48.	1.0	91
166	NO PROTECTIVE EFFECT OF BREASTFEEDING ON INHIBITOR FORMATION IN SEVERE HEMOPHILIA. Pediatric Hematology and Oncology, 2005, 22, 575-580.	0.3	6
167	Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica, 2005, 90, 846-50.	1.7	36
168	Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thrombosis and Haemostasis, 2004, 92, 305-310.	1.8	65
169	Dose and outcome of care in haemophilia - how do we define cost-effectiveness?. Haemophilia, 2004, 10, 216-220.	1.0	19
170	Variability in Bleeding Pattern of Severe Hemophilia.. Blood, 2004, 104, 3094-3094.	0.6	4
171	Incidence and Outcome of Discontinuation of Prophylactic Treatment among Young Adults with Severe Hemophilia.. Blood, 2004, 104, 3086-3086.	0.6	5
172	Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia, 2003, 9, 376-381.	1.0	57
173	Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia, 2003, 9, 75-82.	1.0	57
174	Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia, 2003, 9, 1-4.	1.0	190
175	Prophylaxis for Severe Hemophilia: Experience from Europe and the United States. Seminars in Thrombosis and Hemostasis, 2003, 29, 049-054.	1.5	25
176	Association between joint bleeds and pettersson scores in severe haemophilia. Acta Radiologica, 2002, 43, 528-532.	0.5	31
177	The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood, 2002, 99, 2337-2341.	0.6	245
178	Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia, 2002, 8, 753-760.	1.0	147
179	Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia, 2002, 8, 745-752.	1.0	182
180	Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiologica, 2002, 43, 528-32.	0.5	13

#	Article	IF	Citations
181	Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. British Journal of Haematology, 2001, 112, 561-565.	1.2	166
182	Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia, 2001, 7, 446-452.	1.0	107
183	Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia, 2001, 7, 544-550.	1.0	86
184	Endogenous clotting factor activity and long-term outcome in patients with moderate haemophilia. Thrombosis and Haemostasis, 2000, 84, 977-80.	1.8	8